Psychedelic Research

The science of psilocybin microdosing unpacked: brain rewiring, mood, focus, and the gap between hype and hard evidence in older adults.

A 2012 comparative study explains why meditation feels like deliberate focus while hypnosis can feel involuntary, highlighting the role of higher‐order awareness, executive function, and agency.

Explore what a meta‐analysis of six trials says about psilocybin therapy for depression—benefits, side‐effects, and the limits of current evidence.

Explore emerging evidence on ibogaine therapy for opioid cravings, PTSD, and depression. Learn about early study outcomes, safety concerns, and limits of the research.

A deep dive into the emerging review on psychedelics for autism—what the data say, why neuroplasticity matters, and the ethical roadblocks ahead.

A 2026 preprint reviews 25 disciplines of altered states, from meditation to psychedelics, and maps the brain mechanisms behind mind‐expanding practices.

Australia’s historic down‐scheduling of psilocybin and MDMA lets GPs refer patients for psychedelic‐assisted psychotherapy. This article explains what the science shows, what it does not, and the practical steps doctors need to take.

A deep dive into the latest ADHD roadmap—how dopamine, genetics and brain imaging could finally give the disorder an objective test.

Explore the latest preprint review on altered states of consciousness, its neurobiological mechanisms, and emerging therapies like MDMA, psilocybin, and Life Between Lives hypnotherapy.

Explore the latest meta‐analysis on DMT therapy for substance misuse, its effect sizes, and why the evidence remains preliminary.